Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 31, 2024, titled "Zydus receives approval from COFEPRIS of Mexico to market Mamitra (Trastuzumab biosimilar) to treat various cancers".
Press Release Jul 31 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received marketing approval from COFEPRIS in Mexico for Mamitra™, a Trastuzumab biosimilar used to treat various cancers. The approval allows Zydus to expand its biosimilar portfolio into new markets, providing access to affordable therapies for cancer patients. Dr. Sharvil Patel, Managing Director, emphasized the company's commitment to addressing unmet healthcare needs globally through innovation. Zydus has previously launched this biosimilar in India under the brand name Vivitra, treating a significant number of patients since its introduction.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jul 23 2024
- Press Release Jul 22 2024
- Press Release Jul 19 2024
- Press Release Jul 17 2024
- Press Release (Revised) Jul 10 2024
Later from Zydus Lifesciences
- Press Release Aug 09 2024
- Press Release Aug 23 2024
- Press Release Aug 27 2024
- Press Release Aug 30 2024
- Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences